Publications by authors named "Amanda Kitten"
Article Synopsis
- Impella devices provide mechanical support for patients with cardiogenic shock or those at high risk during PCI, but anticoagulation protocols for these patients are unclear and complicated by the use of heparin solutions.
- A study with 41 patients using a modified unfractionated heparin (UFH) protocol aimed to evaluate bleeding and thrombotic complications, finding an overall bleeding rate of 29.2% and a thrombosis rate of 4.9%.
- The findings suggest that using a lower initial UFH dose while targeting specific anticoagulation levels can effectively balance therapeutic needs and reduce the complexity of treatment calculations.
Purpose: Type 2 diabetes mellitus (T2DM) is an urgent public health problem and disproportionately affects Mexican Americans. The gut microbiome contributes to the pathophysiology of diabetes; however, no studies have examined this association in Mexican-Americans. The objective of this study was to compare gut microbiome composition between Mexican-Americans with and without T2DM.
View Article and Find Full Text PDFObjective: Despite their efficacy in lowering hemoglobin A1c, recent data suggest that sulfonylureas are associated with cardiovascular risk and hypoglycemia. The objective of this study was to determine whether prescribers decreased sulfonylurea use in favor of newer medications in the United States over seven years.
Research Design And Methods: This cross-sectional study utilized data from the Centers for Disease Control and Prevention's National Ambulatory Medical Care Survey.
Purpose: Gastric acid suppressants are commonly used in the United States, and while generally well-tolerated, long-term use has been associated with infection, bone fractures, and nutrient malabsorption. The purpose of this study was to describe national trends in gastric acid suppressant use over a 7-year period.
Methods: This was a cross-sectional study using data from the National Ambulatory Medical Care Survey from 2009 to 2015.
Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.
Innov Clin Neurosci
February 2018
: Pimavanserin is the first United States Food and Drug Administration (FDA)-approved treatment for Parkinson's disease psychosis (PDP). This article reviews the safety, efficacy, and pharmacology data for pimavanserin and its role in therapy. Initial literature sources were identified via MEDLINE search (1946-September 2016) of pimavanserin and ACP-103 (original molecular designation).
View Article and Find Full Text PDF